Journal of IiME Volume 2 Issue 2 www.investinme.org The Physiology of Exercise Intolerance in Patients with Myalgic Eencephalomyelitis (ME) and the Utility of Graded Exercise Therapy 28 Ciriolo MR, Palamara AT, Incerpi S, Lafavia E, Bue MC, De Vito P, Garaci E & Rotilio G. 1997. Loss of GSH, oxidative stress, and decrease of intracellular pH as sequential steps in viral infection. Journal of Biological Chemistry 272(5): 2700-2708. 29 Cai J, Chen Y, Seth S, Furukawa S, Compans RW & Jones DP. 2003. Inhibition of influenza infection by glutathione. Free Radical Biology & Medicine 34(7): 928-936. 30 Van Konynenburg RA. 2004. Is glutathione depletion an important part of the pathogenesis of chronic fatigue syndrome? Presented at the AACFS Seventh International Conference, Oct. 8-10/2004, Madison, Wisconsin. 31 with glutathione injections. CFIDS Chronicle January/February 1998. 32 Cheney PR. 1999. Evidence of glutathione deficiency in chronic fatigue syndrome. American Biologics 11th International Symposium, Vienna, Austria. Tape No. 07-199: available from Professional Audio Recording, P.O. Box 7455, LaVerne, CA 91750. 33 Spence V & Stewart J. 2004. Standing up for ME. Biologist 51(2): 65-70. 34 25% ME Group. 2004. Severely affected ME (myalgic encephalomyelitis) analysis report on a questionnaire issued January 2004. 25% ME Group, Troon, Ayrshire, UK. pp. 8. 35 Jain AK, Carruthers BM & Van de Sande MI. 2004. Fibromyalgia Syndrome: Canadian Clinical Working Case Definition, Diagnostic and Treatment Protocols-A Consensus Document. Journal of Musculoskeletal Pain 11(4): 3-107. From CBT, GET And Human Rights: by R. Mitchell and V. Mitchell from http://www.investinme.org/Documents/PDFd ocuments/CBT%20GET%20and%20Human%20 Rights.doc Contrast the intellectual and scientific rigour applied in the approval process for the licensing of drugs for clinical use, with the lack of scientific and intellectual rigour applied in the NICE draft with regard to the recommendations for the use of Psychological Therapy in CFS/ME. When compared with the extensive clinical trialling over many years and the independent scrutiny a drug therapy is subjected to, the small and heavily criticised evidence base used to justify the recommendation of CBT and GET for CFS/ME in the NICE draft is seen to be totally inadequate. In respect of informed consent, it cannot arise. There simply cannot be informed consent Salvato P. 1998. CFIDS patients improve since there are important ethical, safety and regulatory questions arising from these treatments, to be addressed. Ethical and safety questions such as those raised in the MRC Neuroethics Report 2005 should be paramount. It is hard to envisage any Independent authority clearing a drug for Human testing or use without ethical and safety issues, like those surrounding Psychological Therapy, being resolved. By ignoring these serious issues with regard to Psychological Therapy, we believe that, as drafted, the Guidelines violate the right of clinicians and patients to the highest, safest standards of Medical practice and care, amounting to a violation of their Human Rights. This is a Human Rights issue. Without an answer to whether this type of therapy is ‘acceptable to Society’ and if it is, without an effective Regulatory framework governing its development and use, there is the serious risk that sick and vulnerable people everywhere will be vulnerable to exploitation and abuse at the hands of the vagaries of power, politics and prejudice. Invest in ME (Charity Nr. 1114035) Page 60/74

61 Publizr Home

You need flash player to view this online publication